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Background: The prevalence of sexual dysfunction in patients with COPD is high and its significance has not been
sufficiently stressed. The aim of this study is to investigate the incidence of erectile dysfunction (ED) and the factors
affecting its frequency in COPD patients.
Methods: Seventy patients with COPD and 68 healthy volunteers were included in the study. The International
Index of Erectile Function questionnaire was used to evaluate ED, and the Beck Depression Inventory was used to
evaluate depression.
Results: The smoking rate was higher and oxygen saturation (SaO2) and body mass index (BMI) were lower in
the COPD group. Blood tests revealed higher levels of follicle stimulating hormone (FSH), luteinizing hormone
(LH), and estradiol. Testosterone level was lower but it was not statistically significant. Various degrees of ED
were detected in 78.6% of COPD patients and 55.8% of the controls. Depression was more common in the
COPD group. There was a negative correlation between forced expiratory volume in 1 sec (FEV1) level and
ED and between SaO2 and ED in the COPD group. A positive correlation was noted between age and ED
in both groups. No significant correlation was found among hormonal status and FEV1, ED, depression, SaO2,
or BMI.
Conclusions: The present study provides further confirmation that COPD is a risk factor for erectile dysfunction. When
establishing a treatment plan for improving the pulmonary function of COPD patients, sexual dysfunction and
depression, which are usually neglected but diminish quality of life, should also be addressed.
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Chronic Obstructive Pulmonary Disease (COPD) is a
chronic, treatable, and preventable disease characterized
by persistent airflow limitation. It occurs as a result of
long-term exposure to harmful particles or gases (mainly
cigarette smoke) that lead to increased inflammatory
response in the airway [1]. The inflammation seen in
COPD is not limited to the lungs and has systemic aspects
[2]. Comorbidities are defined as one or more concomitant
diseases either directly or indirectly, associated with COPD
[3] and they include cardiovascular diseases, malnutrition,
skeletal muscle dysfunction and loss, cachexia,* Correspondence: drhasankahraman@hotmail.com
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reproduction in any medium, provided the orosteoporosis, anaemia, lung cancer, gastroesophageal
reflux, diabetes, metabolic syndrome, obstructive sleep
apnea, depression, and anxiety [1,3,4]. Systemic disorders
lead to decreased libido and erectile dysfunction (ED) by
affecting the sexual function in males. Hormonal imbal-
ances in systemic disorders are thought to arise from
the testes or hypothalamo–hipophyso–testicular path-
way [2]. Androgens rise to peak levels at around the
ages of 20–40 and start to decline after 40 years of age
in males [5]. Symptoms of androgen deficiency can in-
clude depression, anger, muscle and joint pain, anxiety,
sleep disorders, fatigue, poor concentration and memory,
decreased libido, ED, and reduced ejaculate output volume
and speed [6]. ED is defined as a permanent insufficiency
in achieving and/or pursuing an adequate and necessary
erection in order to have satisfactory sexual activity [7].
Loss of sexual desire and function have been associatedral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with a decrease in libido and erectile function in males,
are also caused by ageing [12,13]. Low levels of testosterone
and ED have been reported in males with respiratory
diseases, such as COPD, asthma, and obstructive sleep
apnea syndrome [9,14]. Dyspnea, coughing, muscle weak-
ness, and diminished physical activity are among the
major causes of decreased sexual activity in patients with
COPD [15].
During the evaluation of COPD patients, physicians
generally ignore some significant comorbidities, such as
sexual dysfunction. A previous study demonstrated that
87% of patients with COPD do not discuss their sexual
problems with their physicians and 78% do not share
these problems with their wives [16]. Few studies have
investigated ED incidence in patients with COPD, and
this topic remains a neglected area of research. The aim
of this study is to assess the causes and frequency of ED
in patients with COPD and to draw attention to this
subject.
Methods
This study was conducted on 70 COPD patients and
68 healthy volunteers who had been referred to the
KahramanmarasSutcu ImamUniversity, Medical School
Pulmonary Disease Clinic and the AfsinStateHospital,
Pulmonary Clinic. The approval for this study was obtained
from the Ethical committee of the University. All partici-
pants signed an informed consent form prior to the study.
Healthy volunteers were patients who had been referred
to the Pulmonary Disease Clinic because of cough and
chest pain of less than 4 weeks. They had no history of
any chronic disease, and no other serious health problem
was detected after the physical, laboratory, and radio-
logical examinations. Patients who had coronary heart
disease, diabetes mellitus, history of alcoholism, impaired
health, or who were receiving any hormonal or psycho-
logical treatments were excluded from the study. The se-
lected patients filled out a questionnaire in order to identify
their socio-demographic status. Body mass index (BMI)
and oxygen saturation (SaO2), measured from the finger,
were recorded.
Pulmonary function tests
A pulmonary function test (PFT) was performed in com-
pliance with American Thoracic Society criteria using a
spirometry device (ZAN 500; nSpire Health GmbH,
Oberthulba, Germany) [17]. Post-bronchodilator forced
expiratory volume in 1 sec (FEV1), forced vital capacity
(FVC), and FEV1/FVC were measured. A post-broncho-
dilator FEV1/FVC ratio less than 70% of the predicted
value confirmed the diagnosis of COPD. The severity of
COPD was graded based on the GOLD classification as
mild, moderate, severe, and very severe [1].International index of erectile function
The International Index of Erectile Function (IIEF-5) is a
self-applied five-question index developed by Rosen et al.
[18] that is intended to evaluate erectile function. The
maximum score is 25 points, and classification is as
follows: 1–11 points, moderate to severe; 12–21 points,
mild; and 22-–25 points, no ED. Severity was assessed as
follows: 0, no ED; 1.degree, mild ED; 2.degree, mild to
moderate ED; 3.degree, moderate ED; and 4.degree, severe
ED [9,18].
Biochemical analysis
Venous blood samples were obtained from all participants
to measure total testosterone levels, follicle-stimulating
hormone (FSH), luteinizing hormone (LH), and estradiol.
The levels of testosterone, estradiol, and FSH were mea-
sured by enzyme-linked immunosorbent assay (ELISA)
using a Thermo Scientific ® Multiskan FC (Finland), and
LH was measured using the chemiluminescent method
with an Immulite® 2000 (Siemens USA).
Beck depression inventory scale
The Beck Depression Inventory Scale (BDI) is a 21-
question, multiple-choice, self-applied inventory developed
by Beck et al. [18]. It evaluates depression symptoms based
on physical, emotional, and spiritual aspects. An assessment
of the reliability and validity of the Turkish version was
performed by Hisli et al. [19]. The cut-off score is 17 for
this inventory, and a higher score indicates more severe
depression.
Statistical analysis
Findings were evaluated using the SPSS 17.0 software
package. Data were expressed as the mean, range, and
standard deviation. For the statistical assessment, inde-
pendent t-test, Pearson correlation, one-way analysis of
variance, and chi-square tests were applied, and p less
than 0.05 was considered significant.
Results
A total of 138 male subjects, 70 patients with COPD
and 68 control volunteers, were included in the study.
Socio-demographic information of all participants are
presented in Table 1. The age ranges of the volunteers
were 42–81 years for the COPD patients and between
45-80 years for the control group. The COPD group
consisted of patients with a history of smoking. Out of
these, 36 (51.4%) were former and 34 (48.6%) were current
smokers. In the control group, 38 (55.8%) were non
smokers, 20 (29.43%) had quit smoking, and 10 (14.7%)
were current smokers. The duration of smoking abstinence
was 4.7 ± 6.8 years in the COPD group. BMI was signifi-
cantly lower in the COPD group compared to the controls
(p = 0.003). There was a significant difference between the
Table 3 Pulmonary function of the male COPD group
according to GOLD classification
Predicted FEV1 (%) (mean ± SD) n (%)
Mild 86.36 ± 4.3 11 (15.7)
Moderate 64.52 ± 8.25 40 (57.1)
Severe 41.12 ± 6.1 16 (22.9)
Very severe 18.66 ± 5.5 3 (4.3)
Table 1 Socio-demographic findings of the male
participants in both COPD and control group
COPD Control p value
Subjects (n) 70 68 -
Age (years) 63.34 ± 10.13 59.77 ± 10.46 NS
BMI (kg/m2) 25 ± 4.43 27.8 ± 3.46 0.003
Smoking (pack-years) 37.67 ± 16.67 19.57 ± 14.32 0.000
Education (%)
Unschooled (%) 35.7 19.1 0.017*
Elementary school (%) 45.8 47.1
High school or higher (%) 18.5 33.8
BMI, Body mass index; NS, not statistically significant.
*Unschooled group was statistically significant to High school or higher group.
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status (p = 0.017); however, no difference was found based
on the living environment (p = 0.98) (Table 1).
Oxygen saturation was lower in the COPD group,
and the difference was statistically significant (p = 0.000).
Although total testosterone level was lower in the COPD
group compared to the controls, the difference was not
significant (p = 0.17). In the COPD group, FSH, LH, and
estradiol levels were significantly higher compared to the
control group (p = 0.024, p = 0.005, p = 0.000, respectively)
(Table 2). The grading of the COPD patients was made
according to the GOLD classification (Table 3).
Evaluation of IIEF-5 scores showed that 55 (78.6%) of
the COPD patients and 38 (55.8%) of the controls had
various degrees of ED, and the difference was statistically
significant (p = 0.000) (Figure 1). The number of subjects
who were considered to have depression (BDI score ≥17)
was 34 (48.6%) in the COPD group and 16 (23.5%) in the
control group. The difference was statistically significant
(p = 0.003) (Figure 1). The mean degree of ED in the
COPD group was higher than the controls (p = 0.000).
The mean BDI score, demonstrating the depression status,
was higher in the COPD group compared to the controls,Table 2 Pulmonary function and oxygen saturation
findings of the male participants in both COPD and
control group
COPD Control p value
SaO2 (mm Hg) 93.24 ± 2.78 95.78 ± 1,92 0.000
FVC (% pred) 80.94 ± 18.9 94.77 ± 17.01 0.000
FEV1 (% pred) 60.64 ± 18.14 95.47 ± 17.53 0.000
FEV1/FVC (%) 57.66 ± 11.39 80.71 ± 6.18 0.000
Testosterone (ng/mL) 4.69 ± 2.59 5.35 ± 2.81 NS
FSH mIU/mL 12.54 ± 9.78 9.09 ± 6.53 0.024
LH mIU/ml 9.77 ± 6.16 6.64 ± 4.45 0.005
Estradiol (pg/mL) 39.1 ± 20.91 22.75 ± 14.38 0.000
SaO2, Oxygen saturation; LH, Luteinizing hormone; FSH, Follicle-stimulating
hormone; NS, not statistically significant.and the difference was statistically significant (p = 0.000)
(Figure 2).
Correlations
In the COPD and control group, a moderate negative
correlation was found between FEV1 and ED (r = −0.36,
p = 0.00). There was no correlation between the level of
FEV1 and BDI scores (r = −0.15, p = 0.39), but a negative
correlation was found between FVC and BDI scores
(r = −0.25, p = 0.03).In the control group, no correlation
was demonstrated between FEV1 and ED, FEV1 and the
BDI score, or ED and the BDI score.
In both COPD and control group, there was no signifi-
cant correlation between hormone levels and FEV1, ED,
depression, SaO2, and BMI (p > 0.005). However, a nega-
tive correlation was found between SaO2 and ED and
between SaO2 and BDI in the COPD group (r = −0.26,
p = 0.029; r = −0.37, p = 0.037, respectively). Likewise, a
negative correlation was found between SaO2 and ED
in the control group (r = −0.41, p = 0.001).
Age was correlated with both depression and ED in
the control group, (r = 0.26, p = 0.044; r = 0.44, p = 0.00,
respectively). On the other hand, there was a positive
correlation between age and ED in the COPD group
(r = 0.50, p = 0.00), while no correlation was detected
between age and depression (r = −0.12, p = 0.29).
Discussion
Sexuality is a lifelong necessity in order to pursue human
well-being [9]. Factors including ageing and generally poor
health can cause diminished sexual activity, libido, and
ED. Physical and psychological problems, leading to
morbidity, and medications can affect the sexual life of the
patients [20]. A broad-based public study (Massachusetts
Male Ageing Study) an ED prevalence as high as 52% in
males between the fourth and seventh decade of life [21].
Dunn et al. demonstrated that 34% of males (mean age
50) within the general population complained about
sexual problems and the most common complaint was ED
[22]. Both studies showed that ED prevalence increases
with age. In another study, ED prevalence was reported to
be 7.6% between 40 and 49 years, 33.3% between 50 and
59 years, 70.2% between 60 and 69, and 90.1% over 70 years
[23]. In our study we demonstrated that this ratio was
55.8% in the control group (mean age 59 years). In both
Figure 1 Erectile dysfunction and depression features of male participants in the COPD and the control groups. Mild to mod ED: mild to
moderate ED; mod ED: moderate ED. BDI score was ≥17 in depression cases. * p = 0.000; ** p = 0,003.
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correlation between age and ED. The findings of all these
studies support a strong association between age and ED.
COPD is not only a pulmonary obstructive disease
but also a chronic illness, which presents with various
comorbidities involving multiple organs [24]. Some of
the well-defined comorbidities are muscle-joint diseases,
hypertension, and cardiovascular, neurological, and gastro-
intestinal diseases [4,25,26]. As obvious from the GOLD
guide [1] and the previously mentioned studies, sexual
function disorders, such as ED, are not included in the
comorbidities of COPD. Chronic diseases not only disrupt
the natural course of daily life but also frequently cause
deterioration of the sexual life [9]. In a study by Koseoglu
et al. [27], ED was detected in 75.5% of 60 COPD patients
(mean age 63 years), while other studies of patients with
ED found 87% of 95 COPD patients [9], 86% of 50 COPDFigure 2 Degree of erectile dysfunction and depression in the male p
Depression Inventory score. * p = 0.000.patients [28], and 72% of 90 patients [12]. In our study,
the ED ratio was 78.6%, and the mean age was 63 years.
Karadag et al. [9] did not found a significant difference
between the COPD and the control groups based on the
presence of ED, but in their study, the prevalence of
moderate and severe ED was higher in the COPD group
compared to the controls. Similarly, ED prevalence was
significantly higher in our patient group. When we evalu-
ated the severity of ED, the most common grade was severe
ED (35.7%), which was an expected finding.
Sexual activity causes an increase in the cardiopulmonary
load. Energy spent during orgasm is equal to the energy
required for walking with a speed of 5–6 km/h or continu-
ous stair climbing for 3–4 minutes [12,29]. Decreased
exercise tolerance and fear of dyspnea may limit sexual
activity [15]. Furthermore, in this patient population, mis-
perceptions, ignorance, and poor physical or psychologicalarticipants of the COPD and the control groups. BDI score, Beck
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dysfunction [9]. Studies have reported that more severe
disease has a higher ED frequency [9,27]. Likewise, the
present study demonstrated a positive correlation between
the severity of COPD and ED.
In males, testosterone is secreted mainly from the gonads.
LH is released from the pituitary gland and controls
the secretion of testosterone from Leydig cells. FSH
contributes to an increase of testosterone secretion by
inducing the maturation of Leydig cells [2]. In males
testosterone gradually decreases with ageing and in parallel
ED prevalence increases [30]. In a study investigating
the association between plasma sex steroids and ED in
elderly males, free testosterone was significantly lower
and estradiol levels were higher, and this was associated
with ED [31]. Another study demonstrated that testoster-
one levels of male COPD patients were lower than those
of the controls [32]. Similarly, Karadag et al. [2] found
lower levels of testosterone, an insignificant increase in
FSH and LH, and a positive correlation between PaO2 and
testosterone levels in COPD patients. Furthermore, they
demonstrated a significant rise in LH and FSH and an im-
portant decline in testosterone levels during exacerbation
in COPD patients. In our study, the levels of LH, FSH,
and estradiol were significantly higher; however, the
decline in testosterone levels was insignificant in the
COPD patients. Similar to the study by Karadag et al. [2],
our results showed no correlation between the testosterone
level and ED score. In contrast to Karadag et al. [2], we did
not demonstrate a significant correlation between via FEV1
score and hormone levels. This possibly was due to the
lower number of severe COPD patients in our study.
Another factor leading to the sexual problems in COPD
patients could be the low level of SaO2. ED incidence is
reported to rise as the blood oxygen level decreases in
healthy individuals ascending to a high altitude [33]. In
a pioneer study conducted by Semple et al. [7], decreased
libido was noted in nine patients and an absence of a
morning erection was noted in seven out of 10 hypoxemic
patients with COPD. Furthermore, with oxygen support
therapy, serum testosterone levels increased with oxygen
support therapy in all of these patients, sexual dysfunction
improved in three patients, and the return of a morning
erection was obtained in two patients. In our study, we
found a strong significant correlation between hypoxemia
and depression and also between hypoxemia and ED in
the COPD patients. Our findings support the fact that
hypoxia increases ED in COPD patients.
Anxiety and depression are among the most common
comorbidities in COPD. Janssen et al. [34] demonstrated
that depression incidence was 27% in 701 COPD patients
and the incidence was 17.7% in the study of Turan et al.
[35]. In our study, the depression incidence was 48.6% in
the COPD group and 23.5% in the control group, and thedifference was significant. We hypothesized that there
would be a negative correlation between depression and
FEV1; however, no significant correlation was found. On
the other hand, we found a negative correlation between
depression and FVC. We assume that an increased
depressive status in the COPD patients contributed to the
worsening ED.
Some limitations were noted during the evaluation of
the results. The most important ones are the absence of the
following parameters: the BODE index, the six-minute
walking test, the partner status information, and the arterial
blood gas test in both the study and the control group.
Conclusions
GOLD guidelines do not contain information regarding
sexual dysfunction in the comorbidities sections. Conse-
quently, physicians who follow the GOLD guide usually do
not ask patients whether they have any sexual complaints.
This is an important limitation to patients’ quality of
life. Sexual dysfunction and depression should be carefully
questioned when recording the history of patients with
COPD, and this information should be used in therapy
planning.
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